Tralokinumab-ldrm recalls

The FDA has published 1 recall involving Tralokinumab-ldrm since 2026. The latest was reported on 4 Mar 2026. Most were for particulate matter. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.

Total recalls1since 2026

Last 12 months1reported

Class I00% of total

Ongoing1latest 4 Mar 2026

Recalls per month, last 24 months

click a bar for that month

0Nov '24 0 0 0Feb 0 0 0May 0 0 0Aug 0 0 0Nov 0 0 0Feb 1 0 0May 0 0 0Aug 0 0

Severity split

Class I 0 0%Class II 1 100%Class III 0 0%

Why tralokinumab-ldrm is recalled

Particulate Matter1100%

Companies

LEO Pharma1100%

By year

20261100%

Ongoing tralokinumab-ldrm recalls

1 active

Reported	Class	Recall	Company	Reason	Where
4 Mar 2026Drug	CLASS II	Adbry, (tralokinumab-ldrm) injection, 300 mg recalled by Leo PharmaAdbry	LEO Pharma	Particulate Matter	Nationwide

All tralokinumab-ldrm recalls, newest first

1 total

Reported	Class	Recall	Company	Reason	Where
4 Mar 2026Drug	CLASS II	Adbry, (tralokinumab-ldrm) injection, 300 mg recalled by Leo PharmaAdbry	LEO Pharma	Particulate Matter	Nationwide

Should you stop taking Tralokinumab-ldrm?

Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.